Skip to content

Clinical trials

Phase 3 trials in Iran

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Phase: Phase 3 Country / region: Iran Clear all

189 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20031
20042
200510
20068
200711
20086
20097
20105
201110
201214
201312
201411
201512
201610
201710
201810
20199
20207
202111
20225
20235
20243
20255

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed121
Unknown status58
Terminated4
Enrolling by invitation2
Withdrawn1
Not yet recruiting1
Recruiting1
Active, not recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Tehran University of Medical Sciences40
Shahid Beheshti University of Medical Sciences30
Royan Institute20
Cinnagen12
Isfahan University of Medical Sciences10
Rajaie Cardiovascular Medical and Research Center7
Shahid Beheshti University7
Shiraz University of Medical Sciences7
AryoGen Pharmed Co.6
Hormozgan University of Medical Sciences4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Infertility13
Inflammation6
COVID-195
Hepatitis C5
Vitreoretinopathy, Proliferative5
Cardiovascular Diseases4
Infertility, Female4
Angina, Stable3
Atrial Fibrillation3
Coronary Artery Disease3

Trials

Showing 1 to 25 of 189. Each trial links to its page on Pharma Observatory.

89 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.